The price of RxSight Inc. (NASDAQ:RXST) shares last traded on Wall Street rose 2.25% to $13.19.
Based on available information, 5 analysts follow RxSight Inc. (NASDAQ:RXST). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $24.00 and a low of $14.00, we find $22.00. Given the previous closing price of $12.90, this indicates a potential upside of 70.54 percent. RXST stock price is now 3.13% away from the 50-day moving average and 1.25% away from the 200-day moving average. The market capitalization of the company currently stands at $359.69M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Among analysts, 1 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $19.40 as their price target over the next twelve months.
With the price target reduced from $20 to $14, Wells Fargo Downgraded its rating from Overweight to Equal Weight for RxSight Inc. (NASDAQ: RXST). On April 08, 2022, Needham recently initiated its ‘Buy’ rating on the stock quoting a target price of $18.
Insiders disposed of 1,383,388 shares of company stock worth roughly $18.25 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RXST stock. A new stake in RxSight Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $3,134,000. DIMENSIONAL FUND ADVISORS LP invested $213,000 in shares of RXST during the first quarter. In the first quarter, SVB WEALTH LLC acquired a new stake in RxSight Inc. valued at approximately $145,000. HIGHTOWER ADVISORS, LLC acquired a new stake in RXST for approximately $132,000. BNP PARIBAS ARBITRAGE, SNC purchased a new stake in RXST valued at around $86,000 in the second quarter. In total, there are 82 active investors with 49.30% ownership of the company’s stock.
A candlestick chart of RxSight Inc. (NASDAQ: RXST) showed a price of $12.94 on Thursday morning. During the past 12 months, RxSight Inc. has had a low of $9.20 and a high of $16.99. As of last week, the company has a debt-to-equity ratio of 0.42, a current ratio of 8.50, and a quick ratio of 7.60. The fifty day moving average price for RXST is $12.79 and a two-hundred day moving average price translates $13.03 for the stock.
The latest earnings results from RxSight Inc. (NASDAQ: RXST) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.61, beating analysts’ expectations of -$0.69 by 0.08. This compares to -$0.68 EPS in the same period last year. The company reported revenue of $12.62 million for the quarter, compared to $5.79 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 118.03 percent. For the current quarter, analysts expect RXST to generate $10.98M in revenue.
RxSight Inc.(RXST) Company Profile
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Leave a Reply